PE20161221A1 - Anticuerpos de il-21 - Google Patents
Anticuerpos de il-21Info
- Publication number
- PE20161221A1 PE20161221A1 PE2016001575A PE2016001575A PE20161221A1 PE 20161221 A1 PE20161221 A1 PE 20161221A1 PE 2016001575 A PE2016001575 A PE 2016001575A PE 2016001575 A PE2016001575 A PE 2016001575A PE 20161221 A1 PE20161221 A1 PE 20161221A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- refers
- sequence
- amino acids
- Prior art date
Links
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se refiere a un anticuerpo que se une a IL-21 humana caracterizado porque comprende: a) una region variable de cadena pesada (HCVR) que comprende una secuencia de aminoacidos CDRH1, CDRH2 y CDRH3 de SEQ ID NO: 10, SEQ ID NO: 11 y SEQ ID NO: 12, respectivamente; y b) una region variable de cadena ligera (LCVR) que comprende una secuencia de aminoacidos CDRL1, CDRL2 y CDRL3 de SEQ ID NO: 7, SEQ ID NO: 8 y SEQ ID NO: 9. Tambien se refiere a su proceso de preparacion, a un metodo de tratamiento y a una composicion farmaceutica. Dicho anticuerpo tiene alta afinidad y neutralizan a IL-21 humana, siendo utiles en el tratamiento de enfermedades autoinmunes tal como lupus eritematoso sistemico, sindrome de Sjogren, diabetes tipo 1, entre otros
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968550P | 2014-03-21 | 2014-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161221A1 true PE20161221A1 (es) | 2016-11-12 |
Family
ID=54141466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001575A PE20161221A1 (es) | 2014-03-21 | 2015-03-13 | Anticuerpos de il-21 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9394362B2 (es) |
| EP (1) | EP3119806B1 (es) |
| JP (2) | JP6053989B2 (es) |
| KR (1) | KR101859857B1 (es) |
| CN (1) | CN106061999B (es) |
| AP (1) | AP2016009450A0 (es) |
| AR (1) | AR099625A1 (es) |
| AU (1) | AU2015231777B2 (es) |
| BR (1) | BR112016019176A2 (es) |
| CA (1) | CA2939543C (es) |
| CL (1) | CL2016002281A1 (es) |
| EA (1) | EA033335B1 (es) |
| EC (1) | ECSP16075416A (es) |
| ES (1) | ES2774422T3 (es) |
| IL (1) | IL246909A0 (es) |
| MA (1) | MA39342B2 (es) |
| MX (1) | MX2016012120A (es) |
| MY (1) | MY177915A (es) |
| NZ (1) | NZ722518A (es) |
| PE (1) | PE20161221A1 (es) |
| PH (1) | PH12016501820A1 (es) |
| SG (1) | SG11201606705QA (es) |
| TW (1) | TWI646105B (es) |
| WO (1) | WO2015142637A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3689325A1 (en) | 2014-04-08 | 2020-08-05 | Boston Pharmaceuticals Inc. | Binding molecules specific for il-21 and uses thereof |
| WO2017075252A1 (en) * | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibody variant conjugates and uses thereof |
| US11267882B2 (en) | 2016-03-31 | 2022-03-08 | Eli Lilly And Company | Methods of detecting human IL-21 |
| KR20210016557A (ko) * | 2018-05-31 | 2021-02-16 | 글리콤 에이/에스 | 자가면역 질환 치료를 위한 hmo 혼합물 |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2019312692A1 (en) | 2018-08-02 | 2021-03-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| US20220289822A1 (en) | 2019-08-21 | 2022-09-15 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3226367A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| KR20240035825A (ko) | 2021-07-09 | 2024-03-18 | 다인 세라퓨틱스, 인크. | 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US20240318176A1 (en) * | 2021-07-09 | 2024-09-26 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300173C (zh) * | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
| EP2184298A1 (en) * | 2003-03-14 | 2010-05-12 | Wyeth a Corporation of the State of Delaware | Antibodies against human IL-21 receptor and uses therefor |
| ITRM20040586A1 (it) * | 2004-11-29 | 2005-02-28 | Giuliani Spa | Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico. |
| JP5322653B2 (ja) * | 2005-11-28 | 2013-10-23 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２１アンタゴニスト |
| WO2007114861A2 (en) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Il-21 receptor antagonists |
| US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| RU2504552C2 (ru) * | 2007-12-07 | 2014-01-20 | Займодженетикс, Инк. | Моноклональные антитела против il-21 человека |
| DK2796466T3 (en) * | 2007-12-07 | 2018-02-05 | Zymogenetics Inc | HUMANIZED ANTIBODY MOLECULE SPECIFIC TO IL-31 |
| US20130323259A1 (en) | 2011-01-17 | 2013-12-05 | Novo Nordisk A/S | Il-21 ligands |
| JP2014518198A (ja) * | 2011-05-31 | 2014-07-28 | ノヴォ ノルディスク アー／エス | Ｉｌ−２１のエピトープおよびｉｌ−２１リガンド |
-
2015
- 2015-03-04 AR ARP150100643A patent/AR099625A1/es unknown
- 2015-03-06 TW TW104107331A patent/TWI646105B/zh not_active IP Right Cessation
- 2015-03-13 PE PE2016001575A patent/PE20161221A1/es unknown
- 2015-03-13 CN CN201580012207.3A patent/CN106061999B/zh active Active
- 2015-03-13 AU AU2015231777A patent/AU2015231777B2/en not_active Ceased
- 2015-03-13 ES ES15764397T patent/ES2774422T3/es active Active
- 2015-03-13 NZ NZ722518A patent/NZ722518A/en not_active IP Right Cessation
- 2015-03-13 MX MX2016012120A patent/MX2016012120A/es unknown
- 2015-03-13 BR BR112016019176A patent/BR112016019176A2/pt not_active Application Discontinuation
- 2015-03-13 EP EP15764397.4A patent/EP3119806B1/en active Active
- 2015-03-13 US US14/657,075 patent/US9394362B2/en active Active
- 2015-03-13 MY MYPI2016703395A patent/MY177915A/en unknown
- 2015-03-13 JP JP2016514173A patent/JP6053989B2/ja active Active
- 2015-03-13 AP AP2016009450A patent/AP2016009450A0/en unknown
- 2015-03-13 WO PCT/US2015/020383 patent/WO2015142637A1/en not_active Ceased
- 2015-03-13 CA CA2939543A patent/CA2939543C/en active Active
- 2015-03-13 EA EA201691521A patent/EA033335B1/ru not_active IP Right Cessation
- 2015-03-13 MA MA39342A patent/MA39342B2/fr unknown
- 2015-03-13 KR KR1020167025492A patent/KR101859857B1/ko not_active Expired - Fee Related
- 2015-03-13 SG SG11201606705QA patent/SG11201606705QA/en unknown
-
2016
- 2016-07-24 IL IL246909A patent/IL246909A0/en unknown
- 2016-09-09 CL CL2016002281A patent/CL2016002281A1/es unknown
- 2016-09-19 PH PH12016501820A patent/PH12016501820A1/en unknown
- 2016-09-20 EC ECIEPI201675416A patent/ECSP16075416A/es unknown
- 2016-11-29 JP JP2016231655A patent/JP6373944B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161221A1 (es) | Anticuerpos de il-21 | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| JP2020500538A5 (es) | ||
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| BR112019011988A2 (pt) | anticorpo anti-cd73 humana | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| PE20161439A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| PE20161311A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
| PE20180120A1 (es) | Proteinas de union a icos | |
| NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
| PE20181336A1 (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso |